Trastuzumab-deruxtecan (Enhertu)
Other Medications · Approved since 2019
Description
Trastuzumab-deruxtecan is an antibody-drug conjugate that combines the HER2-targeting monoclonal antibody trastuzumab with a potent topoisomerase I inhibitor payload (deruxtecan). In colorectal cancer, it specifically targets HER2-positive metastatic tumors, which represent approximately 2-3% of all colorectal cancers. This medication delivers cytotoxic chemotherapy directly to HER2-overexpressing cancer cells while potentially affecting nearby tumor cells through its bystander effect.
Mechanism of Action
The trastuzumab component binds specifically to the HER2 receptor on cancer cell surfaces, facilitating internalization of the drug conjugate. Once in
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Enhertu |
| Category | Other Medications |
 Status | Off-label |
| Administration | IV |
| Year Approved | 2019 |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.